ZAI LAB LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 273 MXN | +0.74% |
|
-.--% | -46.71% |
| 27/06 | Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing | MT |
| 20/06 | Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -46.71% | 171.77Cr | - | ||
| +2.08% | 9.52TCr | A- | ||
| -4.34% | 3.75TCr | A- | ||
| +77.19% | 2.82TCr | A | ||
| -14.61% | 1.56TCr | C | ||
| -3.46% | 1.36TCr | B- | ||
| -12.31% | 1.15TCr | D+ | ||
| +184.77% | 1.08TCr | D | ||
| -54.13% | 923.34Cr | B | ||
| +6.44% | 909.4Cr | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ZLAB Stock
- ZLAB N Stock
- Ratings Zai Lab Limited
